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Introduction
Adiponectin, a 244-amino acid protein and abundantly 
present in the plasma, is synthesized and secreted exclusively
by the adipose tissue (1,2). Adipocytes and osteoblasts are
both of mesodermal origin (2). Osteoblasts have been de
monstrated to express adiponectin in lower levels than in sub-
cutaneous adipose tissue (2-4). In addition, adiponectin 
receptors are present in human osteoblasts, suggesting that it
has paracrine and endocrine effects on bone-forming cells (5).
Rickets is characterized by a failure in mineralisation of 
osteoid tissue (6). Vitamin D deficiency (VDD) is the 
predominant cause of rickets and is associated with an increase
in osteoblastic activity and possibly with serum adiponectin 
levels (7,8). The aim of this study was to investigate the effect
of vitamin D treatment on serum adiponectin levels in children
with vitamin D deficiency rickets (VDDR).
Methods
The study was approved by the Ethical Committee of
Ataturk University Faculty of Medicine and written informed
consent was obtained from the parents of all participants.
This longitudinal study was conducted between March 2007
and February 2008. The study group consisted of otherwise
healthy children aged 2-24 months whose body weight and
height values were between 3rd and 97th percentiles, and
who were diagnosed as VDDR. Clinical rickets was diagnosed
in children who showed two or more of the following 
findings: craniotabes (in infants over 2 months), bilateral 
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widened wrists, frontal bossing, bowing of the legs, 
pathologic fractures, hypocalcemic tetany, hypocalcemic
convulsions, and Harrison’s sulcus. Infants with familial
forms of rickets and those with secondary VDD due to 
kidney, liver and gastrointestinal system diseases were
excluded from the study. 
The anthropometric indices of the patients were 
recorded before and after therapy. Weight was measured
using an electronic scale (Seca Model 770, Hamburg, 
Germany). Length (±0.1 cm) was measured using a 
body-length measurer by a paediatrician. Body mass index
(BMI) was calculated as body weight (kg)/square of length
(m
2). Radiological and laboratory investigations were carried
out in all cases diagnosed as VDDR. Radiological evidence
of rickets by radiography of the left wrist included two or
more of the following signs: generalized osteopenia, fraying
and cupping of the distal ends of the radius or ulna. To 
confirm the diagnosis of VDDR biochemically, serum calcium
(Ca), phosphorus (P), alkaline phosphatase (ALP), serum 
intact parathyroid hormone (iPTH), and 25-hydroxyvitamin D
(25(OH)D) were measured in all patients. VDD was defined
as a serum 25(OH)D level less than 10 ng/ml (9).
All patients were treated with an intramuscular single
dose (300,000 IU) of vitamin D3, and 50 mg/kg/day of 
elementary calcium lactate administered orally for ten days.
The patients were invited to the clinic one month after the
initiation of therapy. Serum Ca, P, ALP, iPTH, and 25(OH)D
were re-measured and radiography of the left wrists were
re-evaluated. If the serum Ca, P, and 25(OH)D concentrations
increased while serum iPTH and ALP concentrations 
decreased compared to pre-treatment values, and if a 
calcification zone along the metaphyseal-diaphyseal border
was detected radiologically, the patient was considered to
be healed. 
Measurement of serum adiponectin levels, and 
biochemical and hormonal parameters 
Blood samples were obtained before and after 
treatment. Biochemical tests were studied immediately.
For hormone measurements, serum samples were 
transferred into Eppendorf tubes and stored at -20 
oC until
assayed. Adiponectin was measured by ELISA using the
kits and protocol from ORGENIUM Laboratories, Inc. 
(AviBion Human Adiponectin (Acrp30) ELISA Kit, Helsinki,
Finland). Serum Ca, P, and ALP levels were measured using
the calorimetric method. Serum iPTH was determined with
chemiluminescence enzyme immunoassay method using
the iPTH kit (IMMULITE 2000 Intact PTH Kit, DPC Co.,
USA). Serum 25(OH)D level was determined by competitive
binding RIA (Gamma-B, 25(OH)D RIA, Immunodiagnostic
Systems, UK). 
All the calculations were made by using SPSS (version
15.0, Chicago, IL, USA) for Windows. The Wilcoxon-Smirnov
test was used for the significance level of the differences
between longitudinal patterns. Correlations between two
variables were tested by Pearson’s correlation coefficient.
The results were expressed as mean±SD; p<0.05 was 
considered statistically significant.
Results
Twenty-one cases with rickets completed the study.
Mean follow-up duration was 28±2 (25-32) days. The median
chronological age at referral was 7.3 (2-16) months. 
Anthropometric parameters before and after therapy are
shown in Table 1. Weight and height increased significantly
after treatment, but there was no change in BMI. Biochemical
markers measured before and after treatment are shown in
Table 2. No significant correlations were found between 
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Table 1. Anthropometric indices of the patients before and after treatment (mean±SD)
Parameter Pre-treatment Post-treatment p
Body weight (kg) 7.65±1.66 8.2±1.51 <0.001
Length (m) 0.66±0.53 0.68±0.05 <0.001
BMI (kg/m
2) 17.30±1.66 17.57±1.45 0.118
Table 2. Changes in the biochemical and hormonal parameters of the patients during the study period (mean±SD)
Parameter Pre-treatment Post-treatment p
Ca (mg/dl) 5.82±0.59 9.95±0.64 <0.001
P (mg/dl) 4.58±0.97 5.84±0.98 <0.001
ALP (U/l) 1221±475.7 533±164.8 <0.001
iPTH (pg/ml) 192.4±113.4 35.19±16.37 <0.001
25(OH)D (ng/ml) 4.21±1.84 52.73±17.63 <0.001
Adiponectin (mg/ml) 150.1±66.14 84.29±9.06 <0.001serum adiponectin and 25(OH)D levels before and after 
treatment, or between delta adiponectin concentrations
and delta 25(OH)D levels. Serum adiponectin concentration
was positively correlated with mean ALP level in patients
with VDDR before treatment (r=0.722, p<0.001). 
Discussion
To our knowledge, this is the first study investigating
the relationship between serum 25(OH)D and adiponectin
concentration in children diagnosed with VDDR. We found
that serum adiponectin levels decreased significantly in 
cases with VDDR on treatment. 
VDDR, a growing bone disease, is mostly encountered
in the developing regions of the world (8,10). The etiology
of nutritional rickets (NR) has a spectrum range from 
isolated VDD to isolated Ca deficiency (11,12). In Turkey,
VDD is the cause of almost all NR cases (13), while in Egypt
and Nigeria, the condition is due to calcium insufficiency
and/or VDD (14). In this present study, dietary Ca levels of
the patients were not measured and all patients with NR
were accepted as VDDR.
Both adipocytes and osteoblasts are cells of mesodermal
origin  (2). Cells of mesenchymal origin share many 
characteristics in gene expression during differentiation.
Even though their phenotypes may differ markedly, mature
adipocytes and osteoblasts express and secrete several
common factors. This is a sign of close relationship between
these cells (15). The experimental results of adiponectin 
expression and secretion from bone-forming cells 
demonstrate that adiponectin is not adipocyte specific, and
that it may have important functions in normal bone cells (2).
This is underlined by the recently reported association between
serum adioponectin concentration and bone mineral density
(16). It was also reported that adiponectin expression in 
osteoblasts is much lower than in subcutaneous adipose 
tissue, an expected finding considering that it is synthesized
and secreted exclusively by the adipose tissue (2-4). In this
study, serum adiponectin concentration significantly 
decreased after treatment, while there was no difference in
BMI scores of the cases before and after treatment. This 
finding suggests that the increased adiponectin level in VDDR
may result from bone tissue with increased osteoblastic 
activity. In this study, it was shown that mean serum 
adiponectin concentration was positively correlated with mean
ALP level that was the sign of the high osteoblastic activity in
cases with VDDR before vitamin D therapy. The effect of the
vitamin D treatment on the osteoblastic activity, in turn, on the 
adiponectin level after the treatment of rickets confirm that 
increased serum 25(OH)D level is associated with 
decreased osteoblastic activity. In previous studies (1,5), it was
reported that presence of adiponectin receptors in 
human osteoblasts suggests that adiponectin has paracrine
and endocrine effects on bone-forming cells (5). It was also
shown that adiponectin increased mRNA expression of ALP
and mineralisation activity of mouse osteoblasts, indicating
that adiponectin may have a potential to activate 
osteoblasts (1).
On the other hand, it was reported in some studies that
adiponectin increases the osteoclastic activity, and primary
osteoclasts express both adiponectin R1 and adiponectin
R2 receptors, suggesting that adiponectin may directly 
target osteoclast cells (1,2,17). Clinical studies show that
patients with VDDR have high bone resorption markers 
indicating high bone turn over (7,18). In the present study,
serum adiponectin concentration before treatment was 
significantly high and decreased on therapy. 
In conclusion, this is the first study investigating the 
relation between serum 25(OH)D and adiponectin 
concentration in children diagnosed with VDDR. The results
of the study show that serum adiponectin levels are 
increased in patients with VDDR, a finding which is 
probably related to increased osteoblastic activity. The 
regulation of bone metabolism by adipokines is still largely
unknown and future studies are needed to better 
understand the relationship between adipokines and bone. 
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